Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$13.58 USD

13.58
2,151,456

-0.18 (-1.31%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $13.73 +0.15 (1.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

by Zacks Equity Research

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

by Zacks Equity Research

bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

by Zacks Equity Research

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

by Zacks Equity Research

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

by Zacks Equity Research

Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

by Zacks Equity Research

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

by Zacks Equity Research

J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

by Zacks Equity Research

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

by Zacks Equity Research

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

by Zacks Equity Research

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

by Zacks Equity Research

Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.

Zacks.com featured highlights include Qifu Technology, Willdan Group, H&E Equipment Services, Cimpress and Applied Industrial Technologies

by Zacks Equity Research

Qifu Technology, Willdan Group, H&E Equipment Services, Cimpress and Applied Industrial Technologies are part of the Screen of the Week article.

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Adma Biologics (ADMA) closed at $6.04 in the latest trading session, marking a -1.15% move from the prior day.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Gain

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are QFIN, WLDN, HEES, CMPR, AIT.

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

by Zacks Equity Research

Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.

Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data

by Zacks Equity Research

Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

by Zacks Equity Research

Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.